Research progress in psoriatic arthritis-related cardiovascular damage

Ming Liu1, Man Han2, Xiao-Mei Leng3

1Department of Rheumatology and Immunology, Central Hospital of Shaoyang, Shaoyang, Hunan 422000, China; 2Division of Rheumatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100730, China; 3Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.

To the Editor: Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis, mainly manifested as peripheral arthritis, enthesitis, finger or toe inflammation, and spinal arthritis.[1] PsA may develop at any age, peaking at age of 30 to 50 years with no significant gender difference, but the spinal involvement is more frequent in men. The prevalence of PsA in China is about 1.23‰. About 75% of patients with PsA develop rash before arthritic onset whereas 10% after arthritis development.

PsA patients are closely associated with a variety of comorbidities, including obesity, metabolic syndrome, cardiovascular disease (CVD), cerebrovascular disease, and peripheral vascular disease. According to European League Against Rheumatism recommendations for the management of PsA with pharmacological therapies, non-musculoskeletal manifestations including skin, eyes, and gastrointestinal tract should be monitored during the treatment of PsA patients while complications such as metabolic syndrome, CVD or depression should also be considered.[2] In order to provide guidance for clinical practice, we summarize recent literatures on PsA-related cardiovascular damage.

PsA is a chronic recurrent inflammatory disease mainly mediated by T cells and other immune cells. A variety of effector cells and inflammatory mediators participate in PsA pathogenesis, among which proinflammatory adipoctyks produced by adipocytes such as resistin, leptin, and visfatin contribute to the disease progression. In addition to its inhibitory function on regulatory T cells, leptin has been shown to promote the proliferation of CD4+ T cells and natural killer cells, increase neutrophil chemotaxis, and induce macrophages to produce tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and IL-12. Consequently, TNF-α and IL-6 can inhibit adiponectin production by adipocytes, thus increasing the disease severity of cutaneous-only psoriasis (PsC). On the other hand, increased TNF-α production leads to the elevation of serum leptin level, which promotes the local inflammatory response and enhances the progression of PsC. Notably, both body mass index (BMI) and leptin levels are found significantly higher in PsA patients than those in PsC patients. A close correlation between PsA and CVD is possibly due to the shared pathophysiological pathways between them. The increased levels of C-reactive protein (CRP), IL-6, TNF-α and other inflammatory mediators in CVD patients can affect vascular endothelial cells and lead to endothelial dysfunction, and promote the occurrence and progression of major vascular events. Currently, it is not clear whether certain specific inflammatory cytokines are involved in the development of PsA-CVD. It has been reported that human cartilage glycoprotein-39 (YKL-40), a biomarker of endothelial dysfunction, is significantly increased in PsA patients.[3] As a risk factor for CVD, the metabolic syndrome is characterized with endothelial dysfunction. Since YKL-40 is associated with adiponectin and leptin, key adipokines in the pathogenesis of psoriasis,[4] further studies are needed to determine whether increased YKL-40 levels can indicate a higher risk for CVD in PsA patients.

Patients with psoriasis are often presented with lipid metabolism disorder. The prevalence of metabolic syndrome or hyperglycemia, hypertension, atherosclerosis,
Current treatment for PsA includes non-steroidal anti-inflammatory drugs (NSAIDs), conventional disease modifying anti-rheumatic drugs (cDMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs). NSAIDs can inhibit inflammatory reaction and relieve joint pain, swelling, and morning stiffness in PsA patients. The long-term and continuous use of NSAIDs reduce radiographic progression in patients with ankylosing spondylitis. The cyclooxygenase-2 inhibitors can reduce the side effects of NSAIDs on gastrointestinal tract, but may increase the incidence rate of cardiovascular events such as thrombosis, hypertension, heart failure, and heart failure. However, other studies have reported that celecoxib does not increase the risk of cardiovascular events.\(^{[8]}\)

In clinical applications, cDMARDs include methotrexate, acitretin and cyclosporin, and so on. The methotrexate can reduce the incidence of CVD while its long-term use may lead to higher risk of end organ toxicity. It is reported that acitretin often causes hyperlipidemia whereas cyclosporin can lead to hypertension, hyperlipidemia, and even cause myocardial damage through the production of reactive oxygen species. Therefore, more attention is needed to monitor the side effects of these drugs on cardiovascular system.

Both bDMARDs and tsDMARDs provide a new option for the treatment of PsA. Several studies have observed the effects of these new therapies on lipid metabolism disorder and cardiovascular events in patients with PsA. Spanakis et al compared the effect of infliximab on 60 patients with refractory rheumatism and found that HDL levels showed a long-term upward trend. Furthermore, anti-TNF-a therapy is beneficial in reducing the incidence rate of CVD in these patients. Recent studies show that IL-12/23 inhibitor ustekinumab has potential effects on cardiac protection and does not increase the risk of serious cardiovascular adverse events, but further studies with longer-term follow up are required to confirm this finding. In addition, IL-17A inhibitor secukinumab does not cause any significant changes in blood glucose, blood pressure, body mass index, and blood lipid in patients with PsA after...
3 years of treatment. Since systemic inflammation may affect cardiac metabolism and increase the risk of CVD in patients with PsA during the natural course of disease, the observed cardiac safety of secukinumab from clinical studies supports its application as a new treatment option for patients with PsA accompanied with cardiac metabolic risk factors. A recent study has evaluated the influence of treatment with JAK inhibitors on cardiovascular events, in which the incidences of deep vein thrombosis and pulmonary embolism were higher in baricitinib treatment group than those in placebo.\(^9\)

Patients with PsA often have metabolic diseases with increased mortality rate after serious cardiovascular complications [Figure 1]. Therefore, how to evaluate and control the cardiovascular risk of patients with PsA remains a challenge in clinical management. Moreover, further clinical trials are needed to determine the therapeutic potentials of newly developed JAK and phosphodiesterase-4 inhibitor in the treatment of PsA patients with CVD.

**Conflicts of interest**

None.

**References**

1. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deol C, Reston J, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res 2019;71:2–29. doi: 10.1002/acr.23789.

2. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McHnes I, Smolen JS, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:700–712. doi: 10.1136/annrheumdis-2020-217159.

3. Kytzikou A, Patsatsi A, Sotiriadis D, Gouls DG. Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies. Dermatology 2017;233:378–389. doi: 10.1159/000481882.

4. Imai Y. YKL-40 is a serum biomarker reflecting the severity of cutaneous lesions in psoriatic arthritis. J Dermatol 2013;40:294–296. doi: 10.1111/1346-8138.12061.

5. Baran A. Effect of psoriasis activity on serum adiponectin and leptin levels. Postepy Dermatol Alergol 2015;32:101–106. doi: 10.5114/ pda.2014.40960.

6. Andreassen OA, Desikan RS, Wang Y, Thompson WK, Schork AJ, Dale AM, et al. Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLoS One 2015;10:e0123057. doi: 10.1371/journal.pone.0123057.

7. Szentpetery A, Healy GM, Brady D, Haroon M, Gallagher P, Fitzgerald O, et al. Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity. Arthritis Rheumatol 2018;70:396–407. doi: 10.1002/art.40389.

8. Nussen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Lincoff AM, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016;375:2519–2529. doi: 10.1056/NEJMoa1611593.

9. Chen M, Dai SM. A novel treatment for psoriatic arthritis: Janus kinase inhibitors. Chin Med J 2020;133:959–967. doi: 10.1097/ CM9.0000000000000711.

How to cite this article: Liu M, Han M, Leng XM. Research progress in psoriatic arthritis-related cardiovascular damage. Chin Med J 2020;133:3001–3003. doi: 10.1097/CMS.0000000000001215